Insilico Medicine completed a large Hong Kong IPO and immediately turned proceeds into a multiyear R&D tie‑up with Servier focused on oncology. The company raised roughly $292–293 million in the Hong Kong listing and said the funds will be used for clinical R&D, generative AI model development and pipeline advancement. Servier committed up to $888 million in potential milestones and will lead clinical validation and commercialization of any candidates emerging from the collaboration. The transaction pairs Insilico’s Pharma.AI discovery stack with Servier’s clinical and regulatory capabilities and signals continued investor appetite for AI-driven drug discovery platforms in Asia and Europe.